Abstract
The σ2 receptor is an enigmatic protein that has attracted significant attention because of its involvement in diseases as diverse as cancer and neurological disorders. Unlike virtually all other receptors of medical interest, it has eluded molecular cloning since its discovery, and the gene that codes for the receptor remains unknown, precluding the use of modern biological methods to study its function. Using a chemical biology approach, we purified the σ2 receptor from tissue, revealing its identity as TMEM97, an endoplasmic reticulum-resident transmembrane protein that regulates the sterol transporter NPC1. We show that TMEM97 possesses the full suite of molecular properties that define the σ2 receptor, and we identify Asp29 and Asp56 as essential for ligand recognition. Cloning the σ2 receptor resolves a longstanding mystery and will enable therapeutic targeting of this potential drug target.
Funder
HHS | National Institutes of Health
Vallee Foundation
Harvard Brain Science Initiative
Esther A. and Joseph Klingenstein Fund
Welch Foundation
National Science Foundation
BrightFocus Foundation
Texas Health Catalyst Program
Publisher
Proceedings of the National Academy of Sciences
Reference49 articles.
1. A Brief History of G-Protein Coupled Receptors (Nobel Lecture)
2. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog;Martin;J Pharmacol Exp Ther,1976
3. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain
4. Abramson Cancer Center of the University of Pennsylvania (2014) Imaging of in vivo sigma-2 receptor expression with 18F ISO-1 positron emission tomography (PET/CT) in primary breast cancer. Clinical trial NCT02762110. Available at https://clinicaltrials.gov/ct2/show/NCT02762110?term=NCT02762110&rank=1. Accessed November 2, 2016.
5. Cognition Therapeutics (2016) Clinical trial of CT1812 in mild to moderate Alzheimer's Disease. Clinical trial NCT02907567. Available at https://clinicaltrials.gov/ct2/show/NCT02907567?term=NCT02907567&rank=1. Accessed November 2, 2016.
Cited by
231 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献